Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

Abstract High tumor mutation load (TMB-H, or TMB ≥ 10) has been approved by the U.S. FDA as a biomarker for pembrolizumab treatment of solid tumors, including non‑small cell lung cancer (NSCLC). Patients with cancer who have immunotherapy-resistant gene mutations cannot achieve clinical benefits eve...

Full description

Bibliographic Details
Main Authors: Xia-ye Miao, Hao Wu, Bi-cheng Ye, Qian-wen Yi, Fang-nan Lin, Yi-lin Wang, Chuan-li Ren, Yan-fang Jiang, Ang Li
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-25050-3

Internet

https://doi.org/10.1038/s41598-022-25050-3

Similar Items